90%Confidence
0Views
FDASource
2026-03-20Date
Summary
Harbin Jixianglong's Semaglutide recall due to incomplete validations reveals significant regulatory compliance failures for a high-demand compound. This creates supply chain risks for compounding pharmacies and highlights quality concerns with Chinese API manufacturers.
Actionable: Avoid sourcing Semaglutide from Harbin Jixianglong until they demonstrate complete regulatory compliance.
AI Confidence: 90%
Data Points
firmHarbin Jixianglong Biotech Co., Ltd.
classificationClass II
statusOngoing
distributionNationwide within the United States
productSemaglutide, For Rx compounding use only, packaged in a) 1g, NDC 84385-106-01; b) 5g, NDC 84385-106-02; c) 10g, NDC 84385-106-06; d) 25g, NDC 84385-1
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now